New diabetes drug shows promise in phase 2 trial
NCT ID NCT07018453
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new medication, SHR-3167, against a standard long-acting insulin (insulin degludec) in people with type 2 diabetes who already use basal insulin. The goal is to see which one controls blood sugar better and is safer. About 173 adults aged 18-65 with type 2 diabetes for at least 6 months are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, 400000, China
-
Zhongshan Hospital Affiliated to Fudan University
Shanghai, Shanghai Municipality, 200032, China